Biohaven Ltd

Research Biohaven Ltd (BHVN) on Bullrun: market cap USD 2.17B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.17B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 738.82M-USD 610.15Mn/a-6.86USD 229.96MUSD 284.61MUSD 52.07M
FY2024USD 0-USD 846.42M-USD 586.50Mn/a-9.28USD 99.13MUSD 36.58MUSD 423.44M
FY2023n/a-USD 408.17M-USD 334.77Mn/a-5.73USD 248.40MUSD 30.88MUSD 427.98M
FY2022n/a-USD 570.28M-USD 303.76Mn/a-12.75USD 204.88Mn/aUSD 538.77M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.17Bn/an/an/a
20252025-12-31USD 1.50Bn/an/an/a
20242024-12-31USD 3.78Bn/an/an/a
20232023-12-29USD 3.43Bn/an/an/a
20222022-12-30USD 946.07Mn/an/an/a

About Biohaven Ltd

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Biohaven Ltd's market cap?

Biohaven Ltd's market capitalization is USD 2.17B.

What does Biohaven Ltd do?

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.